MA-SENTIENT-JET
25.7.2022 15:02:13 CEST | Business Wire | Press release
Sentient Jet , a Directional Aviation company and category innovator, is set to surpass its notable 2021 sustainability efforts of offsetting one of, if not the highest amount of emissions of any private aviation company with the first half of 2022 on the rise. As a multi-million-dollar annual investment at no cost to its card owners, Sentient Jet’s strong commitment to sustainability continues to set a new industry standard while offering a more thoughtful way to fly.
Sentient Jet launched its emissions-neutral sustainability initiative at the start of 2021 and promptly achieved the largest emissions offset of any private aviation company, with a 300% offset across 30,000 legs flown through the year.
Sentient’s offsets represent the equivalent of planting 345,000 acres and nearly 5,000,000 trees in the U.S. or providing the energy for an entire average U.S. town for a full year, according to current U.S. Census Bureau estimates for 2021. Sentient Jet’s carbon offset program supports a variety of renewable energy and forest conservation projects around the world and continues to fund projects to mitigate not only CO2 but non-CO2 impact and improve communities globally.
“We chose to focus on a more comprehensive offsetting program, as we knew this was the best method to help reduce the footprint of our client’s flights while also taking definitive steps to reducing emission levels. Within 18 months we’re extremely pleased with the success of this program, but of course we’re always looking for ways to improve and evolve our ongoing sustainability efforts,” said Andrew Collins, President and CEO of Sentient Jet. “We hope Sentient Jet’s sustainability efforts can become an example for what the private aviation industry as a whole can accomplish in terms of making meaningful steps toward reducing overall emissions and prioritizing our planet.”
At the heart of Sentient Jet’s unique sustainability initiative is the company’s investment and partnership with environmental leader 4AIR , the first and only rating system focused on comprehensive sustainability in private aviation. Sentient Jet’s carbon offset program goes beyond traditional aviation sustainability programs by offsetting all aviation emissions, including water vapor, aerosols, and nitrous oxide, which together account for two-thirds of the emissions an aircraft produces when flying.
“Sentient Jet continues to demonstrate true leadership by committing all of its flights to 4AIR’s Emissions Neutral level on behalf of its clients. Sentient goes beyond just carbon neutrality, addressing the impact from CO2 and non-CO2 emissions in a truly comprehensive fashion,” says Kennedy Ricci, President, 4AIR.
Jet Card owners can book by calling (866) 602-0044 or visiting www.sentient.com .
About Sentient Jet
Founded in 1999 with the invention of the Jet Card, and now an integral part of Directional Aviation, Sentient Jet is one of the most innovative private aviation companies across the globe. The Sentient Jet Card offers clients the flexibility and convenience of flying private for their personal and business air travel needs along with a host of unique digital booking tools, including an industry-first with instant, automated text-based booking , a unique sustainability program, and an outstanding service heritage. Sentient Jet is known for its commitment to safety and is guided by an Independent Safety Advisory Board with former FAA and NTSB officials. Sentient Jet’s extensive network of certified operators ensures that clients will always have access to executive aircraft that meet their rigorous standards for safety and quality. Visit sentient.com for more information. You can also follow Sentient Jet on social media platforms, including Twitter , Facebook and Instagram . Download the Sentient Jet Mobile App: iOS | Android .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom